News and Events

MLM will be well-represented at the highly anticipated return of the Biomarkers & Immuno US: In-Person conference in San Diego, October 3rd and 4th. Dr. Laura Kurth, PhD, Vice President of Laboratory Operations, Minneapolis will also be present along with Isabel Struik, VP of Sales and Marketing and Drew Bosso, Business Development Director. 
 Dr. Lisa Jennings, PhD, MLM’s Chief Scientific Officer will be presenting on the topic: Receptor Occupancy Assays to Improve Dose Selection and Pharmacologic Monitoring in Immunotherapy.
Immunotherapy & Receptor Occupancy Assays
Immunotherapy employs the use of antibodies that target receptors on immune cell subsets and alter their functions.
Assays that assess the binding (receptor occupancy) and the biologic effect of a therapeutic are necessary as part of the drug development continuum.
Prior to receptor occupancy (RO) assay development, it is critical to understand the therapeutic mechanism of action (MoA) and reagent availability to ensure a well-defined, reproducible assay.
Optimization and validation of a RO assay will greatly improve dose selection and drug effectiveness in clinical trial settings.